Cluster page — medicines optimisation
High-risk drug monitoring
Scope
What 'high-risk' means in NHS prescribing safety
High-risk drugs are medicines where a narrow therapeutic window, defined monitoring requirements, or a high-consequence interaction profile means that a missed dose, missed monitoring or missed interaction can cause serious avoidable harm. Methotrexate myelosuppression, lithium toxicity, amiodarone-induced thyroid disease, DOAC bleeding in CKD progression and warfarin INR derangement are the typical exam-question presentations; in practice they are also the most common medicolegal cases against general practice.
NHS England and the MHRA expect every primary care provider to operate a structured HRD monitoring system: an up-to-date register of HRD patients, drug-specific monitoring schedules per BNF/MHRA, automated recall, hard-stop logic preventing re-issue when monitoring is overdue, and pharmacist-led action on abnormal results. PCN clinical pharmacist teams are the operating layer for this work.
HRD register
Drugs typically on the PCN HRD monitoring rota
- Methotrexate — FBC, U&E, LFTs every 12 weeks once stable
- Other DMARDs (sulfasalazine, leflunomide, azathioprine, hydroxychloroquine)
- Lithium — 6-monthly level, TFTs, U&E
- Amiodarone — 6-monthly TFTs, LFTs; annual CXR/PFTs in selected
- Oral anticoagulants (DOACs and warfarin) — renal function, INR, bleed risk
- Ciclosporin / tacrolimus / mycophenolate — shared-care monitoring
- High-dose opioids (>120 mg morphine equivalent daily) — quarterly review
- ACE-i + potassium-sparing diuretic combinations in CKD
HRD KPIs
What good HRD performance looks like
Frequently asked questions
HRD monitoring — FAQs
Which medicines are 'high-risk drugs' in primary care?+
Typically: methotrexate and other DMARDs, lithium, amiodarone, oral anticoagulants (DOACs and warfarin), high-dose opioids, ciclosporin and other transplant immunosuppressants, ACE-inhibitors with potassium-sparing diuretics in CKD, and gentamicin/vancomycin where prescribed in primary care. Local ICB lists may extend.
What monitoring is required for each HRD?+
Each drug has a defined monitoring profile per BNF/MHRA — e.g. methotrexate requires FBC, U&E, LFTs every 12 weeks once stable; lithium requires 6-monthly levels, thyroid and renal function; amiodarone requires 6-monthly TFTs and LFTs. PCNs operate against a consolidated SOP covering all in-scope HRDs.
Who delivers HRD monitoring in a PCN?+
The pharmacy technician runs the recall and overdue list; the clinical pharmacist reviews results, makes prescribing changes within IP scope, and escalates abnormal results. Hard-stop logic prevents re-issue when monitoring is overdue.
What KPIs apply to HRD monitoring?+
Percentage of HRD patients with current monitoring against drug-specific standard, overdue rate, action-rate on abnormal results, hard-stop activation frequency, and incident rate associated with HRD prescribing.
Talk to our Service Development team
30-minute discovery call. We'll show you how BCS maps to your PCN's specific priorities.